Objective-To determine the safety and efficacy of intra-articular injections of hyaluronan in the treatment of osteoarthritis of the knee. Methods-A randomised double-blind placebo-controlled trial was carried out on 91 patients with radiologically confirmed osteoarthritis of the knee who were recruited from the outpatient clinics. Results-It was found that weekly intraarticular injections of20 mg ofhyaluronan of Mr = 750 000 (Hyalgan) in 2 ml of buffered saline performed no better than the inert vehicle alone over a five week period. The principal side effects of a transient increase in pain and swelling in the affected knee was observed in 47%/o of the treatment group compared with 22% of the placebo group. A few patients with radiologically mild disease treated with Hyalgan appeared to experience medium to long-term symptomatic improvement over matched placebo controls as judged by a delayed return to previous NSAID therapy or analgesia other than paracetamol. Patient numbers in the survival groups, however, were too small to be meaningful. Conclusion-It is concluded that intraarticular administration of this preparation of 750 kD hyaluronan offers no significant benefit over placebo during a five week treatment period, but incurs a significantly higher morbidity, and therefore has no place in the routine treatment of osteoarthritis.
Hyaluronan (hyaluronate, hyaluronic acid) is a linear repeating disaccharide, 3-D-glucuronyl-3-D-N-acetylglucosamine, of high molecular weight which may range up to 10 megadaltons. Its physical properties vary discontinuously with its chain length.' Hyaluronan is secreted continuously into the joint space by elements of the synovium with some contribution by the chondrocyte.2 It comprises the major macro-molecular species of the synovial fluid and is responsible for the unique visco-elastic properties of what is mainly a simple plasma dialysate.3 -5 Its clinical use was suggested by the finding that hyaluronan was reduced in concentration and in chain length in the synovial fluids of arthritic patients.' 6 It was thought that the intra-articular administration of exogenous high-molecular-weight hyaluronan might restore the rheological environment of the joint ('visco-supplementation') thereby improving its load-transmitting function.
The first trials of intra-articular hyaluronan in human osteoarthritis were reported with mildly encouraging results by Helfet7 and by Peyron and Balazs8 in 1974 . Several studies with various preparations of hyaluronan from different sources and of differing molecular weights have since been conducted.9 '-8 Although these variances in molecular weight and other methodological variations in trial design make direct comparisons difficult, there has been a broad consensus in the studies published that this treatment is well-tolerated and reduces the pain of osteoarthritis. Some of these studies indicated that symptomatic relief may be long lived, lasting six months or more.
Many of the published clinical studies suffered from small patient numbers (less than 50) or, in the case of the multi-centre studies, the inevitable difficulties of inter-observer variation. For this reason, we conducted a randomised double-blind placebo-controlled trial of weekly intra-articular hyaluronan of defined molecular weight (approx. Mr = 750 000) in a number of patients recruited from a single centre sufficient to invest the study with the power to discriminate a clinically meaningful treatment efficacy.
Methods and materials STUDY MEDICATION
Hyaluronan of approximately Mr = 750 000
Daltons was supplied as Hyalgan, a stable and highly purified sodium salt of hyaluronan in phosphate buffered saline extracted from rooster combs, by Fidia SpA. Abamo Terme, Italy. Quality control analysis following purification confirmed the range of hyaluronan molecular weights in the samples used as 500 000-750 000 Daltons, and that no detectable residual protein remained from the original extraction. At the third visit (week 0), following a two week washout period, only patients meeting the above selection criteria entered a preassigned randomisation schedule which ensured that within each block of ten patients, equal numbers would receive treatment and placebo. A full medical historv was taken from the patient. Before receiving an injection, the patient had a general physical examination by the investigating physician; blood was collected for extended haematological and biochemical profiles.
After randomisation, the patient's most severely affected knee was aspirated through a green (21 G) needle inserted into the patellofemoral space via the medial approach using an aseptic technique. Through the same needle, the patient received an intra-articular injection of either 20 90(1(00)"',) 1minutes) and on standardised active and 8 (32"') 13 (50",',) passive movement was recorded as a 100 mm 63-9 (1 9) 72 1 (1 7) 60 0 ( 1 9) 67 ( (1 7) VAS score by the patient at each visit. With the patient's knee fully extended, patello-femoral 10 (50W/o) 20 (80"') 15 19(395", ,) 25 (I 00"0) 20 (1000") 26 (100"(,) patella with the patient again recording pain
acts of daily living on a 100 mm VAS were recorded, as was the weekly quantity of escape analgesia required. On the eighth visit (week 5), one week after the final injection, the affected knee was aspirated only. Blood was again taken for analysis identical to the pretreatment samples. Global subjective assessments of treatment efficacy by both patient and metrologist were recorded.
Following this period, all patients were reviewed at one, three and five months post treatment. As in the treatment phase, pain at rest, on movement and on vertical and horizontal pressure was assessed by the metrologist using the patient's VAS scores, as was interference with daily life. The range of flexion of the knee was recorded. A global assessment of the state of the knee relative to previous visits was made by both patient and metrologist. The knee was aspirated if a clinically evident effusion was present.
Any adverse event experienced by the patient was reported to the 'blinded' metrologist and recorded by the 'unblinded' clinical investigator. All adverse events were then reported to the principal investigator who made any final decision to withdraw the patient. All patients were offered the opportunity to withdraw from the study at each visit throughout the treatment and follow up periods. Alternative analgesia or anti-inflammatory treatment was permitted during the follow up but not during the treatment period.
Throughout the study, all patient assessments (apart from the general physical examination at the third visit) were made by the metrologist who was 'blind' to the treatment received. As the physician drawing up and administering the injections could distinguish treatment from placebo by its greatly increased viscosity, he had played no part in patient assessment at any time. The appearances of the solutions were identical, however, and therefore gave no clue to the patient as to which she was receiving.
DATA HANDLING AND STATISTICAL METHODS
All data from the case record forms were scrutinised by an independent clinical monitor operating to the standards of Good Clinical Practice. Statistical analysis of the data was performed using the TABULATE, GLM and FREQ programmes of the SAS statistics and data management system (PC Version 6&04) on an IBM-compatible personal computer.
All tests of the null hypothesis were twotailed with confidence intervals set at the 95% level.
At the outset of the trial, it was calculated that a sample size of 100 patients, 50 receiving Hyalgan and 50 receiving placebo, would be expected to invest the study with 900/o power to detect a mean treatment difference of 13-1 mm in VAS scores. Time did not permit us to recruit the target figure. However, it was felt that the final study population was adequate to detect a clinically meaningful treatment difference if one existed. Seven patients were withdrawn from the study during the treatment period. Five, all on Hyalgan, withdrew of their own volition because they were unable to tolerate the injections. Two patients, both on placebo, were withdrawn by the investigating physician because their synovial fluid analyses suggested a diagnosis other than osteoarthritis: gout in one case and an unidentified crystal arthritis in the other. The final study population therefore numbered 84.
Twenty eight patients, 13 on Hyalgan and 15 on placebo, were lost to the study in the five month follow up period due to non attendance. Analysis of the follow up phase has therefore been carried out separately from the treatment phase.
Analyses of the diary data revealed that both the Hyalgan and placebo groups improved in their mean VAS scores for all five papameters measured over the five week treatment period. There was, however, no statistically significant difference in the behaviour of the two groups at any point during that period. The patient diary mean VAS scores for the start (week 0) and the end (week 5) of the treatment period are summarised in table 2.
Although analysis of the VAS scores for pain at rest and for pain on both active and passive movement of each group assessed at each visit 
48-6 (6 6) 60-9 (6 5) 53 9 (5 6) 63-0 (5-1) Table 2 summarises the patients' diary data for the week before the start (that is, the first injection at week 0) and the week before the finish (that is, the week following the last injection at week 4) of the five week treatment period. Although all patient groups improved, there was no significant difference at the 5% level of the behaviour of the treatment and placebo groups at any point during that period. 22-6 (6-1) 32-9 (6 9) 39-2 (7-1) 28-7 (6-1) Table 3 summarises the patients' visit assessment data for the week before the start (that is, the first injection at week 0) and the week before the finish (that is, the week following the last injection at week 4) of the five week treatment period. Although all patient groups improved, there was no significant difference at the 5% level in the behaviour of the treatment and placebo groups at any point during that period. There was no significant change either in the range of flexion of the treated knee or in the number of paracetamol tablets taken as escape analgesia in either group over the treatment period. The distributions of weekly paracetamol consumption within each of the Severity Groups at the beginning (week 0) and end (week 5) of the treatment period are summarised in table 4.
The only adverse event attributable to treatment was a transient increase in pain and/ or swelling in the treated knee; this usually lasted less than four days. Such local adverse events occurred in 21 (47%) of the 45 Hyalgan treated patients, and in 10 (22%) of those who received placebo. In the Hyalgan group, five of those affected (24%) described this effect as mild; 14 (67%) described it as moderate, and two (9%) as severe. In the placebo group, one affected patient (10%) described the effect as mild; eight (80%) described it as moderate, and one (1 0%) as severe. There were no significant changes in any patient of any parameter of the full blood counts and biochemical profiles carried out at the beginning and at the end of the treatment period.
When asked for a global assessment of their progress at the end of treatment, 57/5% of the 40 patients treated with Hyalgan remaining in the trial said they felt better. This was mirrored by 61-5% of the remaining 44 members of the placebo group who also reported improvement. There was therefore no significant treatment difference. The clinical metrologist's global assessments likewise detected no significant treatment difference between the Hyalgan and placebo groups.
During the five-month follow up period, 28 patients (13 treated with Hyalgan and 15 receiving placebo) failed to continue attending the clinic. These patients were deemed therefore to have withdrawn from the study of their own volition. A separate analysis was carried out on the data of those patients who continued to the end of the follow up study.
Comparison of the rates of return to NSAID therapy, or analgesia other than paracetamol alone, in the surviving Hyalgan versus placebo cohorts of Severity Group I (fig) showed that the delay in seeking further treatment was Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: Figure 1 The figure represents a survivalfunction analysis ofthose patients with radiologically judged early or mild disease (Severity Group I; n = 28) showing that the rate of return to previously prescribed or other NSAIDs, or analgesia other than paracetamol, is significantly slower (p < 0 01) in the Hyalgan treated cohort (n = 14). A similar analysis ofthe Severity Group II (moderate to severe; n = 28) cohorts showed no significant difference between the patients receiving Hyalgan (n = 13) and placebo (n = 15 That Hyalgan performed no better than saline in the treatment phase of the study where both groups improved suggests two possible explanations: 1) that saline injection is itself a therapeutic manoeuvre at least as efficacious as Hyalgan, or 2) that a placebo effect was operating quite independent of the injections sufficient to skew the results of both groups swamping any difference between the two. If the former is true, then Hyalgan offers no advantage over saline. If the latter is the case, and a number of authors have commented on the 'personal attention factor' in trials treating chronic painful conditions, any difference between Hyalgan and saline would be so small as to be clinically insignificant.
In the five month follow up period, no statistically significant difference was found in the pain and functional parameters assessed with one exception. The return to previous NSAID therapy, or alternative analgesia other than paracetamol alone, was significantly delayed in the Hyalgan treated patients of 
